No price history available.
Key financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SGDm | 45 | 57 | 55 | 56 | 28 | 39 | N/A | N/A |
| Operating profit | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SGDm | 5 | 6 | 5 | 4 | -19 | -13 | N/A | N/A |
| EPS reported | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its operations are structured into two distinct divisions: Banking and Diagnostics. The Banking division is responsible for the collection, processing, storage, and analysis of vital biological samples such as cord blood, cord lining, and various tissue samples. Meanwhile, the Diagnostics division furnishes an array of diagnostic tests, encompassing genetic and metabolic screenings for newborns, pediatric vision and hearing assessments, allergen testing for children, and genetic evaluations for talent identification. Beyond these core services, Cordlife also engages in corneal lenticule banking, gut microbiome storage, and offers lifestyle-focused genetic screening for adults. The company further provides "Moms Up," a mobile application designed to supply parenting information and resources pertinent to health, wellness, and lifestyle needs. Completing its diverse portfolio, Cordlife offers medical laboratory services, marketing support, property investment, alongside specialized consulting and research and development in the medical and pharmaceutical sectors.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its operations are structured into two distinct divisions: Banking and Diagnostics. The Banking division is responsible for the collection, processing, storage, and analysis of vital biological samples such as cord blood, cord lining, and various tissue samples. Meanwhile, the Diagnostics division furnishes an array of diagnostic tests, encompassing genetic and metabolic screenings for newborns, pediatric vision and hearing assessments, allergen testing for children, and genetic evaluations for talent identification. Beyond these core services, Cordlife also engages in corneal lenticule banking, gut microbiome storage, and offers lifestyle-focused genetic screening for adults. The company further provides "Moms Up," a mobile application designed to supply parenting information and resources pertinent to health, wellness, and lifestyle needs. Completing its diverse portfolio, Cordlife offers medical laboratory services, marketing support, property investment, alongside specialized consulting and research and development in the medical and pharmaceutical sectors.